Class Action Lawsuit Filed Against Capricor Therapeutics, Inc.: Bragar Eagel & Squire, P.C. Encourages Investors to Reach Out
In a significant development, law firm Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) over allegations of securities fraud. The lawsuit, which was filed in the United States District Court Southern District Of California, claims that the company made false and misleading statements and concealed material adverse facts concerning its lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
According to the lawsuit, Capricor provided investors with material information that was misleading. The company allegedly failed to disclose four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. As a result of these misrepresentations, investors who purchased Capricor shares between October 9, 2024, and July 10, 2025, may have suffered significant losses.
On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the Biologics License Application (BLA) specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025.
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. Investors who purchased or otherwise acquired Capricor shares and suffered a loss can contact Brandon Walker or Marion Passmore for information about the claims and their rights or interests.
Institutions or private individuals who acquired Capricor shares between October 9, 2024, and July 10, 2025, and who want to know about their rights in the related class action lawsuit should contact the law firm Kirby McInerney LLP or Faruqi & Faruqi, LLP before the deadline (around September 15, 2025). These firms notify and represent investors affected by alleged securities fraud related to Capricor’s statements on their drug Deramiocel and the FDA's rejection of its approval.
Bragar Eagel & Squire, P.C. encourages investors who have questions or concerns about the Capricor lawsuit to contact them directly. It is important to note that prior results do not guarantee similar outcomes for future clients. The class action lawsuit covers all persons and entities who purchased or otherwise acquired Capricor securities between October 9, 2024, and July 10, 2025.
For updates on the case, you can follow Bragar Eagel & Squire, P.C. on LinkedIn, X, and Facebook. For news updates, you can follow Brandon Walker, Esq. on LinkedIn and X. Contact information for Bragar Eagel & Squire, P.C. includes email ([email protected]), telephone (212) 355-4648, and a contact form on their website (www.bespc.com). Bragar Eagel & Squire, P.C. encourages investors who suffered losses in Capricor to contact them directly to discuss their options.
